Document is current
Any future updates will be listed below
-
Authors
Bear, Adham S. https://orcid.org/0000-0002-3137-449X
Blanchard, Tatiana
Cesare, Joseph https://orcid.org/0000-0002-5569-1422
Ford, Michael J.
Richman, Lee P.
Xu, Chong
Baroja, Miren L.
McCuaig, Sarah https://orcid.org/0000-0002-2304-7739
Costeas, Christina
Gabunia, Khatuna
Scholler, John
Posey, Avery D. Jr. https://orcid.org/0000-0001-8711-629X
O’Hara, Mark H.
Smole, Anze
Powell, Daniel J. Jr. https://orcid.org/0000-0002-5966-8908
Garcia, Benjamin A.
Vonderheide, Robert H.
Linette, Gerald P. https://orcid.org/0000-0001-6147-6115
Carreno, Beatriz M. https://orcid.org/0000-0002-8123-2035
- License Information
-
More Information
Article History
Received: 23 April 2020
Accepted: 16 June 2021
First Online: 16 July 2021
Competing interests
: R.H.V. reports having received consulting fees or honoraria from Medimmune and Verastem; and research funding from Fibrogen, Janssen, and Lilly. He is an inventor on a licensed patent relating to cancer cellular immunotherapy and cancer vaccines, and receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody. A.S.B., R.H.V., G.P.L., and B.M.C. have filed a patent application (PCT/US2020/014988) related to the targeting of KRAS for immunotherapy entitled “Compositions and Methods for Targeting Mutant RAS”. A.S., A.D.P., and D.J.P. have filed a patent application (PCT/US2019/026378) that incorporates discoveries related to the NFAT reporter system used in this study entitled “Methods and Compositions Comprising a Viral Vector for Expression of a Transgene and an Effector”. M.J.F. is a founder and an employee of MS Bioworks. All other authors have no competing interest to declare.
